Breaking AI & Tech News Analyzed

The Lead The World Health Organization (WHO) has approved the first malaria treatment for babies, marking a significant milestone in the global fight against the disease. Coartem Baby, developed by Novartis and the Medicines for Malaria Venture (MMV), is designed for infants as small as 2kg (4.4lb) and comes in sweet cherry-flavoured tablets that can be dissolved into liquids, including breast milk. The Event Details Coartem Baby contains two antimalarial drugs, artemether and lumefantrine. The treatment has been shown to be safe and effective for newborns and young infants, addressing a critical gap in malaria care. According to the WHO, up to 18% of children under six months in parts of Africa are infected with malaria, but there has historically been no safe treatment for the smallest of them. The Data Analysis Malaria remains a significant public health challenge, particularly in sub-Saharan Africa. In 2024, there were 610,000 deaths from malaria, about three-quarters of which were under-fives in Africa. The approval of Coartem Baby is expected to significantly impact malaria treatment and prevention efforts, particularly in regions with high rates of malaria. The Impact Analysis The introduction of Coartem Baby is a major breakthrough in the fight against malaria. Dr Tedros Adhanom Ghebreyesus, the WHO director general, noted that "for centuries, malaria has stolen children from their parents, and health, wealth and hope from communities." The approval of this treatment offers new hope for communities affected by malaria and brings the global health community closer to achieving its goal of eliminating the disease. The Prediction With the WHO prequalification of Coartem Baby, public-sector procurement of the treatment is expected to increase in many countries with high rates of malaria, particularly in sub-Saharan Africa. Novartis has committed to making the treatment available "on a largely not-for-profit basis in malaria-endemic regions." As more countries introduce Coartem Baby into their health systems, the impact on malaria-related mortality and morbidity is expected to be significant.

The UK Biobank Data Breach: A Minor Setback One thing Britain is exceptionally good at is collecting and using health data for research, studying cohorts of people over many decades. A shudder of alarm rippled through the research world at the news this week that UK Biobank’s data had been put up for sale on China’s Alibaba site, with the science minister, Patrick Vallance, saying that more attempts to sell the data in China were expected. Understanding the Breach and Its Impact Biobank dashed to reassure its 500,000 members, and as a longtime volunteer I received a message not only explaining what had happened but listing some of the invaluable research findings and remedies that had already sprung from our data. Remarkably, a representative for Biobank told me that only about 100 people inquired about withdrawing, and after each was spoken to, only 50 actually backed out – pretty impressive. Prof Sir Rory Collins, Biobank’s chief executive, says he will personally speak to any anxious participant. The Value of Biobank Data The list of good done using Biobank data includes a blood test revealing motor neurone disease years before symptoms arise, a single gene behind almost all Alzheimer’s cases and a score to decide which overweight people have most risk factors and should be first for weight-reduction drugs. Challenges and Future Directions Longitudinal studies have been a research jewel, allowing projects such as studying children born in the same month who are then followed throughout their lives. In the UK we have followed groups of people from 1946, 1958, 1970, 1989-90 and 2000-2002 and there is now a new study recruiting 30,000 babies this year. The organisation Use My Data, which founded by cancer patients grateful for research that saved their lives, campaigns to get people to join research projects, helping researchers devise trustworthy transparent data systems. The Future of Health Data Research Summon up your public spirit. A population-wide study recruiting now is Our Future Health, seeking 5 million volunteers, so sign up here. I’ve already done so – it’s simple, just a blood sample and a questionnaire gets you a £10 token. Everyone benefits.

The Politicization of Science Donald Trump’s war on science has been vicious and hugely damaging, but it is worth noting that he has lost some of its biggest battles. Last year, Mr Trump demanded that US federal scientific and medical research funding be cut by about half. But the budget Congress passed in February actually delivered a slight increase in overall funding – although specific Trump targets such as the Centers for Disease Control and Prevention were cut. Resistance from Congress He also continues to chip away at science in other ways such as dismissing the board overseeing the National Science Foundation this week. Maga’s attacks on science have been nakedly political. Its defeats have been politics of a different sort, showing that the bipartisan pro-science consensus is still intact, and for the moment has the power to hold Mr Trump in check. A Global Trend What is happening in the US is not unique. Wherever rightwing populists triumph, science is likely to suffer. Jair Bolsonaro’s rule in Brazil saw him attack scientists and cut environmental funding. In India, Narendra Modi’s Hindu nationalist government purged the theory of evolution from school textbooks. In Britain, Reform UK has already attempted local government cuts, targeting net zero spending. The Changing Role of Scientists Scientists have tended to avoid party politics for a specific reason. Historians identify an implicit scientific social contract that emerged in western states after the second world war, which established the state as the main funder of research, but in theory discouraged direct political interference by government. Many scientists believe that engaging in politics endangers this compact: if scientists don’t bother politics, it won’t bother them. A New Era for Science and Politics Scientists are no longer just defending funding. They are defending the idea that science should be independent of politics. What scientists gain by organising protests, speaking to the public through their academies and now running for office is a better understanding of the changing public sphere that they are part of. The public may gain an ally against rightwing populism – and a deeper, more serious engagement with the scientific challenges facing society. Mr Trump set out to tame scientists. He may have politicised them instead.

The New Tool for Obesity-Related Disease Risk A new tool developed by UK researchers can help identify individuals most at risk of obesity-related diseases, such as type 2 diabetes, gout, and stroke. This tool uses a type of AI called interpretable machine learning to analyze data from nearly 200,000 participants of the UK Biobank project. How the Tool Works The researchers applied the AI tool to data from participants with a BMI of 27 or greater, identifying 20 health, lifestyle, and demographic features that could predict the 10-year risk of 18 different obesity-related complications. These features include age, sex, total cholesterol, and creatinine levels. The Data Analysis The team tested the validity of the tool, dubbed Obscore, using UK Biobank data and datasets from two independent health studies. The results showed that participants with the same age, sex, and BMI can have very different risks for various obesity-related conditions. The Impact Analysis The tool could help inform strategies for prioritizing who should receive weight-loss interventions, particularly in cases where access to NHS treatments is limited. According to Prof Nick Wareham, the tool is not about extending the use of particular therapies, but rather about developing and validating a score that can help with more rational resource allocation. The Prediction The researchers believe that their tool could be useful for prioritizing individuals who would benefit most from weight-loss medications. However, Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, noted that substantial further development and validation will be required before such an approach can be translated into routine clinical practice.

The Zoological Society of London (ZSL) celebrates 200 years of a mission that spans scientific research, global conservation projects and public education, highlighted by a new £20 million wildlife health centre at London Zoo.The 1826 Catalyst: Chunee’s Death and the Founding of ZSLIn spring 1826, public outrage over the brutal killing of the elephant Chunee at Cross’s Menagerie sparked a movement among scientists and politicians to create an organisation dedicated to the scientific study and humane display of animals. On 29 April 1826, the Zoological Society of London was founded, embodying the era’s call for responsible stewardship of the animal kingdom.Milestones and Numbers: From 2.2 Million Visitors to 2,764 Conservation Projects£20 million allocated to the new wildlife health centre, offering public access to veterinary work.2.2 million visitors to ZSL’s London and Whipsnade zoos last year.2,764 conservation projects operating in over 80 countries.Approximately 5 % of the global wild Asiatic lion population has been born at London Zoo since 1991.A quarter of the world’s Sumatran tiger births are linked to ZSL’s breeding programme.Why ZSL’s Expanding Role Reshapes Conservation and CultureZSL’s influence extends beyond animal care. Its Institute of Zoology drives cutting‑edge research on wildlife disease, while its historic sites inspire artists, writers and architects—from Edwin Landseer to JK Rowling. The society also bridges urban life and nature, reminding city‑dwelling audiences that “the animals we see are real”.Looking Ahead: The Future Impact of the Wildlife Health CentreThe new health centre positions ZSL at the forefront of combating emerging wildlife diseases, a critical need as habitat loss and climate change accelerate pathogen spill‑over. By integrating public education with advanced veterinary science, ZSL aims to deepen global partnerships, expand its breeding programmes and cement its role as a leader in the worldwide fight for biodiversity.

The Pharmaceutical U-Turn: AstraZeneca's UK Investment Reversal Britain's biggest drugmaker AstraZeneca has announced a surprise £300m investment in the UK, marking a significant reversal after the company paused large-scale projects in Britain last year. The pharmaceutical giant had become disillusioned with the business environment, including the availability of new medicines on the NHS and drug pricing, but has now changed course with this substantial commitment to its UK operations. Strategic Investment in Cambridge and Macclesfield Facilities The investment will focus on two existing sites at Cambridge and Macclesfield. AstraZeneca will complete the construction of the Rosalind Franklin building on its Cambridge campus, where it has its headquarters. The company will also build a "lab of the future" at its Macclesfield site that will utilize digital and data tools to advance drug development. This announcement comes after AstraZeneca had paused a £200m investment in Cambridge last September, which had been expected to create 1,000 jobs, and scrapped plans to invest £450m in its vaccine manufacturing facility in Speke, Merseyside in January. Financial Performance and Market Position AstraZeneca's investment decision comes amid strong financial performance. The company reported an 8% increase in revenues to $15.3bn in the three months to March, with 16% growth in oncology and a 15% rise in rare disease treatments. Meanwhile, competitor GSK reported a 5% rise in sales to £7.6bn, with 28% growth in cancer drug sales. These positive financial results may have provided the confidence needed for AstraZeneca to resume significant investment in the UK. UK Life Sciences Sector at a Crossroads The investment represents a significant vote of confidence in the UK's life sciences sector, which has faced uncertainty due to changing regulatory environments and drug pricing policies. The reversal of AstraZeneca's investment pause suggests that recent government initiatives to improve access for patients—including four new drug approvals since the beginning of the year—have had a positive impact. This development could signal a broader trend of renewed pharmaceutical investment in the UK if the government continues to create a favorable business environment. Future Outlook for UK Pharma and Government Relations Looking ahead, this investment could strengthen the relationship between the pharmaceutical industry and the UK government. Pascal Soriot, AstraZeneca's chief executive, specifically thanked the government "for their effort to improve access for patients" and expressed hope for "further enhancing the access and the reimbursement environment." As the UK seeks to position itself as a global leader in life sciences, this partnership between government and industry could serve as a model for future collaborations, potentially attracting more pharmaceutical investment and solidifying the UK's position in the global biopharmaceutical landscape.

The Dark Side of Critical Minerals Critical minerals such as lithium, cobalt, and nickel are becoming the 'oil of the 21st century' as the scramble for precious metals deepens poverty and creates public health crises in some of the world's most vulnerable communities. The Environmental and Health Impacts The investigation by the United Nations University Institute for Water, Environment and Health (UNU-INWEH) concluded that the growing demand for lithium, cobalt, and nickel used in batteries and microchips is draining water supplies, eroding agriculture, and exposing communities to toxic heavy metals. An estimated 456bn litres of water were used to extract 240,000 tonnes of lithium in 2024. About 700m tonnes of waste, enough to fill 59m bin lorries, were generated by global rare-earth production in 2024. The Human Cost The report found that while EVs may reduce emissions by consumers in North America and Europe, the environmental and health costs are borne by communities far away, in the mining regions of Africa and Latin America. In the Democratic Republic of the Congo, one of the world's biggest cobalt producers, extraction has caused the widespread contamination of rivers used for drinking, fishing, and irrigation. About 64% of people in the country lacked basic access to water in 2024. 72% of those near mining sites reported skin diseases. 56% of women and girls reported gynaecological problems. The Future Outlook The UN is warning that the transition to green energy cannot be at the expense of vulnerable communities and the environment. “Critical minerals are quickly becoming the oil of the 21st century,” said Kaveh Madani, director of UNU-INWEH. “What we are selling as a solution to sustainability is actively hurting people somewhere else in the world. How can we then call the transition green or clean?”

A Gradual Path to a Smoke‑Free Generation Gains Broad SupportThe new tobacco and vapes bill sets a yearly increase in the minimum legal age for buying tobacco, meaning anyone born on or after 1 January 2009 will never be able to purchase cigarettes or vapes legally. From 2027 the age will rise by one year annually, creating a permanent generational line that will eventually eliminate legal sales across the UK. How the Bill Phases Out Legal Sales by Birth YearThe legislation does not criminalise smoking; it places the burden on retailers. Over time two adults of similar age could receive different treatment based solely on birth year – a deliberate mechanism to drive an invisible decline in smoking prevalence. Public Opinion Numbers and NHS Cost Savings Highlight Policy Appeal52% of smokers support raising the age each year (YouGov 2024).78% of the general public back the idea of a smoke‑free generation.The NHS incurs roughly £2.6bn annually in smoking‑related treatment costs, with broader societal costs estimated at £11bn per year. Why the Incremental Ban Is Reshaping UK Public Health and Political ConsensusDespite a polarized political climate, the bill enjoys cross‑party backing from Conservatives, Labour and Liberal Democrats, and even strong support from many smokers who regret starting early. By targeting the supply side rather than criminalising users, the policy aligns with broader goals of reducing preventable disease burden on an overstretched NHS. Future Outlook: Global Watchers and the Road to a Smoke‑Free UKOther nations, such as the Maldives, are monitoring the UK experiment as a potential template for gradual tobacco phase‑outs. If successful, the approach could inspire similar generational bans worldwide, ultimately delivering a public‑health victory that eliminates legal tobacco sales without direct confrontation. Key TakeawaysLegal purchase age rises by one year each calendar year starting 2027.Broad public and cross‑party support underscores the policy’s political viability.Projected NHS savings and reduced smoking‑related mortality bolster the economic case.International health officials are watching the UK as a pioneering case study.

In a climate where climate denial, vaccine skepticism and "alternative facts" dominate headlines, Helen Pearson shows that the tide of evidence‑based practice is still rising. Drawing on five years of interviews with over 200 experts, she offers concrete steps for citizens, educators and policymakers to push back against the growing rejection of science. The Rise of Anti‑Science Rhetoric in Politics and Public Health Recent statements from high‑profile figures have amplified doubt: Donald Trump labeled climate change a "con job", while U.S. health secretary Robert F. Kennedy Jr. has slashed 25,000 staff positions at science agencies and publicly undermined vaccines. In the UK, only 40% of respondents believe information about science is "generally true". These attacks echo the 1992 backlash against evidence‑based medicine, when a small group of doctors faced accusations of "dangerous innovation". Numbers Showing Declining Trust and Funding Cuts Public trust in scientific institutions fell from 58% in 2018 to 40% in 2025 (Ipsos UK). U.S. federal science staffing reduced by 12% between 2022‑2025, equating to 25,000 jobs lost. Investment in AI‑driven evidence synthesis reached $126 million in 2025, signaling a counter‑trend toward better access to research. Over 70% of English school leaders now report using research to guide decisions, up from 45% in 2010. Evidence‑based anti‑poverty programmes have impacted an estimated 850 million lives worldwide. Why the Erosion of Evidence Matters Across Sectors The decline in trust is not just an abstract concern; it directly affects health outcomes, climate action and economic policy. When citizens reject vaccine data, disease outbreaks become more likely, increasing healthcare costs. Climate denial stalls emissions‑reduction legislation, jeopardizing global temperature targets. In education, ignoring rigorous studies on tutoring and phonics can widen achievement gaps. What Experts Predict for the Future of Evidence‑Based Decision‑Making AI‑powered synthesis tools like Consensus will become mainstream, allowing anyone to query a database of >250 million papers within seconds. Curricula that embed critical‑thinking and "evidence literacy" are expected to be adopted in at least 60% of OECD schools by 2030. Funding bodies are likely to tie grant eligibility to open‑access data sharing, accelerating transparency. Grass‑roots fact‑checking networks will grow, with community‑led platforms verifying claims in real time. Ultimately, Pearson reminds readers that science is a human endeavour—messy, iterative, and sometimes uncertain—but its collective weight still outpaces anecdote. By asking for evidence, checking peer review, and supporting institutions that champion rigorous research, individuals can help tip the balance toward reason.